CClinicalTrials.gg
Status unknownNCT03602677ICG-COLORALUpdated Mar 27, 2023

Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage

An interventional study of ICG fluorescence imaging in Colorectal Cancer, Colorectal Neoplasms and Gastrointestinal Cancer, sponsored by Oulu University Hospital. Status unknown at 2 sites in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Oulu University Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
1,062
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, controlled, parallel, multicenter trial to determine the difference in post-operative anastomotic leakages in colorectal surgery, where anastomosis perfusion is evaluated using indocyanine green fluorescence imaging as an addition to standard surgical practice compared to surgical practice alone.

02

Conditions studied

  • Colorectal Cancer
  • Colorectal Neoplasms
  • Gastrointestinal Cancer
  • Gastrointestinal Neoplasms
  • Diverticulosis, Colonic
  • Gastrointestinal Disease

Keywords

  • Colorectal surgery
  • Anastomosis
  • Anastomosis leak
  • Fluorescence imaging
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All consenting patients in the catchment area of participating hospitals who undergo elective colorectal surgery with planned primary anastomosis are eligible for this study.
  • Of rectal cancer patients only those with pathology in the proximal third will be included in the study (defined by area proximal from peritoneal fold).

Exclusion criteria

Exclusion Criteria:

  • Emergent patients
  • Patients with proven diverticular abscess and colonic fistulas are excluded
  • Patients with planned open surgery are excluded.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,062 participants (estimated)

Study arms

  • Experimental
    ICG fluorescence imaging

    Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.

    Device: ICG fluorescence imaging

  • No intervention
    Standard procedure

    Standard colorectal surgery and anastomosis.

Interventions

  • DeviceICG fluorescence imaging

    The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.

05

What researchers measure

Primary outcomes

  1. Anastomosis leakage rate

    Time frame: 0 to 90 days

Secondary outcomes

  1. Severity of anastomosis leakage

    Grade A-C according to International Study Group of Rectal Cancer

    Time frame: 0 to 90 days

  2. Timing of anastomosis leakage

    Days

    Time frame: 0 to 90 days

  3. Deep surgical site infections

    Yes/no

    Time frame: 0 to 90 days

  4. Hospital readmission rate

    Time frame: 0 to 90 days

  5. Reoperation rate

    Time frame: 0 to 90 days

  6. 30- and 90-day complications according to Clavien-Dindo Classification

    Clavien-Dindo Score from Grade 0 (no complications) to Grade V (Death of a patient). Five grades and additionally Grade III and IV will be divided to a and b.

    Time frame: 0 to 90 days

  7. Operation time

    Time from the start of the operation until the surgeon has ended the operation

    Time frame: 0-600 minutes

  8. Length of hospital stay

    Day of the operation is considered the day 0

    Time frame: 0-365 days

  9. 30- and 90-day mortality

    Time frame: 0 to 90 days

  10. Time to first bowel movement

    Postoperative day when the first bowel movement occurs

    Time frame: 0-30 days

  11. Time to first flatus

    Postoperative day when the first flatus occurs

    Time frame: 0-30 days

  12. Hospital costs

    Time frame: 0 to 90 days

06

Study locations

2 of 2 sites recruiting
  • Central Finland Central Hospital
    Jyväskylä, Finland
    Recruiting
  • Päijät Häme Central Hospital
    Lahti, Finland
    Recruiting
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 15, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03602677
Lead sponsor
Oulu University Hospital
Collaborators
University of Oulu, Central Finland Hospital District, Tampere University Hospital, Turku University Hospital, Hospital District of Helsinki and Uusimaa, Päijänne Tavastia Central Hospital, Seinäjoki Central Hospital, Seinäjoki, Finland
Responsible party
Olli Helminen (MD, PhD, Resident, Surgery, Oulu University Hospital) — Principal investigator
First posted
Jul 27, 2018
Start date
Sep 24, 2018
Primary completion
Jul 1, 2023 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
Mar 27, 2023

Study contacts

Jyrki Kössi, MD, PhD
Contact
jyrki.kossi@phhyky.fi
+358381911
Olli Helminen, MD, PhD
Contact
olli.helminen@oulu.fi
+358142691811
Jyrki Kössi, MD, PhD
principal investigator · Päijänne Tavastia Central Hospital
Olli Helminen, MD, PhD
principal investigator · Oulu University Hospital, Oulu, Finland and Central Finland Central Hospital, Jyväskylä, Finland
Heikki Huhta, MD, PhD
principal investigator · Oulu University Hospital
Juha Rinne, MD
principal investigator · Päijänne Tavastia Central Hospital
Matti Kairaluoma, MD, PhD
principal investigator · Central Finland Central Hospital, Jyväskylä, Finland
Tero Rautio, MD, PhD
principal investigator · Oulu University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion